华润医药：截至二零二五年十二月三十一日止年度全年业绩公告

3320 9,653,0088,403,243 1 26414104–05 622436 662(3)63 2 (a) 2(c) (b) —— (c) 21— 3 (a) 10%10% (b) (a)—(b)—(c)—(d)— (i) •• 7 (a) * * 8 16.5%16.5% 25% 9 —0.072—0.083452,340521,448—0.052—0.154326,691967,507 0.1220.052766327 10 4,042,111,0003,331,270,0006,282,510,4616,282,510,461 4,045,4683,350,857(3,357)(19,587) 4,042,1113,331,270 6,282,510,4616,282,510,461 11 3036530180 03031606190911801813651 0303160619091180 85,853,30380,742,110 (a)30903018018,971,089,00017,581,278,000164,102,000330,791,0006,373,141,0005,254,027,000 GDP5% 2030(AI)+ 1. 269,574.3257,673.34.6%16.8%78.7%4.5% 44,507.840,688.99.4%16.5%0.7 9,653.08,403.214.9%4,045.53,350.920.7%0.640.530.1220.052 2. (1) 51,038.510.2%60.5%1.1 (2) 879284892318310 27,372.513.0%5.6%26.8%17,548.30.2%0.9%0.5%12.0%2,740.424.2%3,377.341.7% a. OTC1619 Bioprojet®®B(r/r LBCL) CD19 CAR-T 10ADC5 b. 32.031.0%3,83644% AIISO 56005 BGM05042030siRNAHiCM–18836— 44214338122FDA34531121IIIpre-NDA51III202512.21DC50292ADC6001DC50292A1DC60011FDA11IIb12.2111212.31A32 B6810%31——14- c. 7,00013GAPS-Na 662.35.0% (CMMM) 14627% 355%47%(ADHD)OTC45%161925%1619180%5 d.AI AI+ AIAI—30%90%60% AIAI——17%AI20500 AIAI0.01mm916% AI1.6 e. FDA50Q107—(The Global Fund)(pH4)4,00020% 3. 28261,248DTP25619210 (1) 220,080.43.2%5.8%0.1 12,210.420.8%(DTP)DTP82.319.4%6.4%0.2 (2) a. TOP360BDTOP100%8133 b. ++BU(MNC)+7,00010(CACA)4SMNCISO37301ISO37001MNC150% c. 38114%SPD()4047IVD11010%10027IVD18 d. C360Be34210%+& e. DTP———8218 4.ESG ESGESG a. ESGESGESGGRITCFDMSCI ESGAAWind ESGAA b. 99912ESG2,500 c. 1018.11,9001.07184 (SBTi)15 ++ 15,843.816,424.7 81.0%70.5% 1.411.41 47.4%52.3% 20,476.317,535.510,066.88,887.810,957.416,838.5 58,820.260,568.52,462.71,997.54.2%3.3% 1,602.61,526.7 85,60072,700 0.1220.052()() 1.01.136300.1391617 (i)(ii) 1617 1617 C1 C.2.1C.2.1 C.3.3 F.1.3 C3 436 662(3)63 406(2)407(2)(3) (www.hkexnews.hk)(www.crpharm.com)